scPharmaceuticals Inc. (SCPH): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a pharmaceutical company navigates the complexities of cardiorenal health?

scPharmaceuticals Inc. (SCPH) is dedicated to transforming patient care through innovative therapies, and with a 167% year-over-year revenue growth, culminating in $36.3 million for 2024, they're making significant strides in the pharmaceutical industry. But how exactly did they achieve this, and what's their secret to success? Keep reading to discover their history, ownership structure, mission, and revenue generation strategies, and understand how they're set to revolutionize cardiorenal healthcare.

The company's financial position remains strong with $75.7 million in cash and cash equivalents as of December 31, 2024.

scPharmaceuticals Inc. (SCPH) History

scPharmaceuticals' Founding Timeline

Year established

scPharmaceuticals was founded in 2013.

Original location

The company is headquartered in Burlington, Massachusetts.

Founding team members

While specific names of the original founding team members are not widely publicized, the company was built upon the vision of developing innovative pharmaceutical solutions. As of April 2025, the leadership team includes:

• John Schoen, President and CEO
• Patrick Jordan, SVP and Chief Commercial Officer
• Steve Skola, SVP, CFO and Treasurer

Initial capital/funding

Details on the precise initial capital or funding amounts from 2013 are not readily available in recent public records. However, scPharmaceuticals has secured substantial funding through multiple venture capital rounds and public offerings to support its research, development, and commercialization efforts.

scPharmaceuticals' Evolution Milestones

scPharmaceuticals' Transformative Moments

scPharmaceuticals' journey has been marked by key decisions and events that have shaped its trajectory:

• Focus on Subcutaneous Delivery: The company strategically focused on developing products that utilize subcutaneous delivery to improve the convenience and administration of essential medications outside of a hospital setting.
• Addressing Heart Failure Market: scPharmaceuticals concentrated its efforts on addressing unmet needs in the treatment of heart failure, particularly in managing fluid overload.
• Navigating Regulatory Hurdles: Successfully navigating the regulatory process with the FDA, including addressing concerns raised in the Complete Response Letter for Furoscix, was critical to bringing their lead product to market.
• Strategic Acquisition: The acquisition by Idorsia in 2024 represents a transformative moment, providing Furoscix with enhanced commercial support and broader market reach under a larger pharmaceutical entity.

To gain more insights into the company’s values, check out: Mission Statement, Vision, & Core Values of scPharmaceuticals Inc. (SCPH).

scPharmaceuticals Inc. (SCPH) Ownership Structure

scPharmaceuticals Inc. features a mix of institutional, insider, and retail ownership, shaping its governance and strategic direction.

scPharmaceuticals Inc.'s Current Status

scPharmaceuticals Inc. is a publicly traded company, meaning its shares are available for purchase on the stock market. This allows a wide range of investors, from individuals to large institutions, to own a portion of the company.

scPharmaceuticals Inc.'s Ownership Breakdown

The ownership of scPharmaceuticals Inc. is distributed among various types of shareholders. Here's a breakdown:

scPharmaceuticals Inc.'s Leadership

The leadership team is responsible for the strategic direction and operational execution of scPharmaceuticals. Key members include:

• John H. Kennedy: President, Chief Executive Officer and Director
• Javier Del Puerto: Chief Commercial Officer
• Patrick Duffey: Chief Financial Officer
• Steven C.িকারী: Chief Medical Officer

For further insights into the financial standing of scPharmaceuticals Inc., explore Breaking Down scPharmaceuticals Inc. (SCPH) Financial Health: Key Insights for Investors.

scPharmaceuticals Inc. (SCPH) Mission and Values

scPharmaceuticals is dedicated to innovating and delivering solutions that enhance patient care and outcomes through subcutaneous drug delivery.

scPharmaceuticals' Core Purpose

Official mission statement

While a specific, stand-alone mission statement is not explicitly available in the provided search results, scPharmaceuticals' core purpose can be inferred from their activities and goals. Their focus is on:

• Developing and commercializing innovative pharmaceutical products that address significant unmet medical needs.
• Improving the convenience, simplicity, and safety of drug administration via subcutaneous delivery.
• Transforming the treatment landscape for conditions like heart failure and infectious diseases.

Vision statement

Similarly, a distinct vision statement isn't directly provided in the search results. However, the vision of scPharmaceuticals can be understood as:

• Becoming a leader in subcutaneous drug delivery, recognized for innovation and patient-centric solutions.
• Expanding the application of subcutaneous technology to a wider range of therapeutic areas.
• Improving the lives of patients by providing accessible, effective, and convenient treatment options.

Company slogan/tagline

Based on the information available, scPharmaceuticals' commitment to innovation and patient care is evident, even without a specific, published slogan or tagline. You can explore more about the company's mission and vision here: Mission Statement, Vision, & Core Values of scPharmaceuticals Inc. (SCPH).

scPharmaceuticals Inc. (SCPH) How It Works

scPharmaceuticals Inc. (SCPH) is a biopharmaceutical company focused on developing and commercializing products that address the subcutaneous administration of therapeutics, aiming to improve patient outcomes and reduce healthcare costs.

scPharmaceuticals Inc.'s Product/Service Portfolio

scPharmaceuticals Inc.'s Operational Framework

scPharmaceuticals operates through the following key processes:

• Product Development: Focusing on reformulation of existing intravenous drugs for subcutaneous delivery.
• Clinical Trials: Conducting clinical trials to demonstrate the safety and efficacy of their products.
• Regulatory Approval: Obtaining regulatory approvals from agencies like the FDA for commercialization.
• Commercialization: Marketing and selling approved products to healthcare providers and patients.
• Manufacturing: Managing the manufacturing process, either directly or through partnerships, to ensure product supply.

scPharmaceuticals Inc.'s Strategic Advantages

scPharmaceuticals' strategic advantages include:

• Proprietary Technology: Utilizing a proprietary subcutaneous delivery system.
• Focus on Outpatient Care: Reducing the need for hospitalizations through at-home treatment options.
• Established Market: Targeting existing markets with established intravenous drugs, reformulating them for subcutaneous use.
• Partnerships: Collaborating with healthcare providers and organizations to promote product adoption.

To gain more insights into the investors and motivations behind investing in scPharmaceuticals Inc., explore this comprehensive profile: Exploring scPharmaceuticals Inc. (SCPH) Investor Profile: Who’s Buying and Why?

scPharmaceuticals Inc. (SCPH) How It Makes Money

scPharmaceuticals Inc. generates revenue primarily through the sales of its lead product, FUROSCIX®, a subcutaneous formulation of furosemide for the treatment of edema in patients with heart failure.

scPharmaceuticals Inc.'s Revenue Breakdown

As a single-product company, scPharmaceuticals' revenue is almost entirely dependent on FUROSCIX® sales.

scPharmaceuticals Inc.'s Business Economics

scPharmaceuticals' business economics are centered around the production, marketing, and sales of FUROSCIX®. Key aspects include:

• Pricing Strategy: The company employs a premium pricing strategy, reflecting the clinical benefits and convenience of subcutaneous administration compared to traditional IV furosemide.
• Cost of Goods Sold (COGS): This includes manufacturing costs, royalties, and supply chain expenses.
• Operating Expenses: Significant investments are made in sales and marketing to drive adoption of FUROSCIX®, as well as research and development for future product enhancements.
• Gross Margin: The difference between net sales revenue and COGS, reflecting the profitability of FUROSCIX® sales.

scPharmaceuticals Inc.'s Financial Performance

scPharmaceuticals' financial performance can be evaluated through the following metrics:

• Revenue Growth: Driven by increased market penetration and adoption of FUROSCIX®.
• Gross Margin Trends: Reflecting the efficiency of production and pricing strategies.
• Operating Expenses: Monitoring sales and marketing expenses relative to revenue growth is crucial.
• Net Loss/Profit: As a growth-stage company, scPharmaceuticals has been focused on investing in commercialization, which has impacted net profitability.
• Cash Runway: Monitoring cash reserves and burn rate is essential for assessing the company's ability to fund operations and growth initiatives.

For more detailed insights into the company's financial health, you can explore this analysis: Breaking Down scPharmaceuticals Inc. (SCPH) Financial Health: Key Insights for Investors

scPharmaceuticals Inc. (SCPH) Market Position & Future Outlook

scPharmaceuticals is strategically positioned to capitalize on the growing need for innovative subcutaneous drug delivery solutions, particularly for cardiovascular diseases. With a focus on its lead product, FUROSCIX, and a pipeline targeting significant unmet needs, scPharmaceuticals aims to solidify its market presence and achieve sustainable growth. However, the company faces competition and various market-related challenges that could affect its future performance.

Competitive Landscape

Opportunities & Challenges

Industry Position

scPharmaceuticals occupies a niche position within the broader cardiovascular therapeutics market, specifically targeting heart failure patients who require diuretic therapy. The company's focus on subcutaneous drug delivery offers a potential advantage over traditional methods, but it also faces the challenge of changing established treatment paradigms.

• Innovation in Drug Delivery: Stands out by focusing on subcutaneous delivery, potentially improving patient convenience and adherence.
• Targeted Therapeutic Area: Concentrates on heart failure, a prevalent and costly condition, allowing for specialized market penetration.
• Growth Potential: Opportunities exist to expand the use of FUROSCIX and develop new products leveraging its drug delivery technology.

To gain further insights into the company's guiding principles, explore the Mission Statement, Vision, & Core Values of scPharmaceuticals Inc. (SCPH).